All In Biotech

NDA 207131 · Baxter Hlthcare Corp

Cefazolin In Dextrose

Cefazolin Sodium · Intravenous

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Aug 7, 2015

Approved uses

4

Original approval plus efficacy supplements

Registered trials

207

37 Phase 3, 20 recruiting

FAERS reports

12,207

11,391 serious, 1,402 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

Cefazolin in Dextrose Injection is a cephalosporin antibacterial indicated for: • Treatment of the following infections caused by susceptible isolates of the designated microorganisms in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved : ( 1 ) ο Respiratory tract infections ( 1.1 ); ο Urinary tract infections ( 1.2 ); ο Skin and skin structure infections ( 1.3 ); ο Biliary tract infections ( 1.4 ); ο Bone and joint infections ( 1.5 ); ο Genital infections ( 1.6 ); ο Septicemia ( 1.7 ); ο Endocarditis ( 1.8 ) • Perioperative prophylaxis in adults and pediatric patients aged 10 to 17 years old for whom appropriate dosing with this formulation can be achieved ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin in Dextrose Injection and other antibacterial drugs, Cefazolin in Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ). 1.1 Respiratory Tract Infections Cefazolin in Dextrose Injection is indicated for the treatment of respiratory tract infections due to Streptococcus pneumoniae, Staphylococcus aureus and Streptococcus pyogenes in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1 , 2.2 , 2.4 and 2.5 ) and Use in Specific Populations (8.4) ] . Limitations of Use Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin in Dextrose Injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent...

Mechanism: Cefazolin is an antibacterial drug [ see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • CEFAZOLIN IN DEXTROSE · CEFAZOLIN SODIUM EQ 1GM BASE/50ML (EQ 20MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • CEFAZOLIN IN DEXTROSE · CEFAZOLIN SODIUM EQ 3GM BASE/150ML (EQ 20MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • CEFAZOLIN IN DEXTROSE · CEFAZOLIN SODIUM EQ 2GM BASE/100ML (EQ 20MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cefazolin" as an intervention, any sponsor and status, largest first.

All 207 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension711
  • drug ineffective679
  • anaphylactic reaction659
  • anaphylactic shock622
  • rash600
  • pyrexia518
  • renal failure488
  • acute kidney injury442
  • off label use424
  • pain417
  • nausea379
  • urticaria361

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004222
2005210
2006255
2007157
2008238
2009224
2010233
2011507
2012462
2013268
2014304
2015373
2016540
2017510
2018700
2019831
2020855
2021805
2022954
20231,008
2024981
2025956
2026614

Recalls

1 FDA enforcement reports for this application.

  • Jul 24, 2026 · Class I · Ongoing

    Presence of Particulate Matter

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Oct 30, 2026

    Cefazolin in Dextrose, Injection, 1g/50 mL (NDC 0338-3503-41). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Oct 30, 2026

    Cefazolin in Dextrose, Injection, 3g/150mL (NDC 0338-0096-06). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Oct 30, 2026

    Cefazolin in Dextrose, Injection, 2g/100mL (NDC 0338-3508-41). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 629 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.